Advenchen 
Welcome,         Profile    Billing    Logout  
 4 Products   1 Disease   4 Products   520 Trials   2068 News 


12345678910111213...3637»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, metatinib tromethamine (BMS-794833) / Simcere
    Journal:  BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway. (Pubmed Central) -  Mar 27, 2024   
    Recently, several TKIs, for instance regorafenib and cabozantinib, have showed clinical interest in treating osteosarcoma and target both vascular endothelial growth factor receptor (VEGFR) and mesenchymal epithelial transition factor (c-MET)...More importantly, BMS-794833 and anlotinib exerted synergistic therapeutic effects against osteosarcoma in vivo. Altogether, this study reveals a new (VEGFR)-targeting drug that can be combined with anlotinib for the treatment of osteosarcoma, which provides an important theoretical basis for overcoming anlotinib resistance.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers. (Pubmed Central) -  Mar 26, 2024   
    The combination of anlotinib and PD-1 inhibitors demonstrated a promising clinical effect compared to fluoropyrimidine-based chemotherapy in the second-line treatment of refractory advanced BTCs. Liver metastases and CEA levels may serve as predictive factors for identifying patients who may benefit from AP therapy.
  • ||||||||||  AL2846 / Advenchen, Sino Biopharm
    Enrollment change, Trial completion date, Trial termination:  A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov) -  Mar 21, 2024   
    P1/2,  N=22, Terminated, 
    This experimental study identified FAM83D as a critical regulator that contributes to the proliferation and progression of SS, suggesting that FAM83D-regulated signaling pathway may serve as a prospective target in SS management. N=192 --> 22 | Trial completion date: Dec 2024 --> Feb 2024 | Recruiting --> Terminated; sponsor adjusts its research and development strategy
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Conmana (icotinib) / Betta Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Biomarker, Journal:  Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer. (Pubmed Central) -  Mar 18, 2024   
    Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) mutation was an independent risk indicator of shorter OS following third-line treatments. Comprehending the tumor evolution in NSCLC is advantageous for assessing the efficacy and prognosis at each stage of treatment, providing valuable insights to guide personalized treatment decisions for patients.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    PARP inhibitors plus anlotinib as bridging therapy for TGF?-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer (Section 2) -  Mar 5, 2024 - Abstract #AACR2024AACR_6960;    
    P1
    Immunocompetent mice bearing ID8 tumors were treated with niraparib (21 days) plus anlotinib (14 days) and euthanized at different timepoints (0, 7, or 14 days since discontinuation) to quantify tumor-infiltrating T cells and profile T cell functions...Replication-deficient NALM6 cells pre-treated with mitomycin C were injected to provide CD19 antigen... PARP inhibitors plus anlotinib as bridging therapy facilitated CAR-T cell infiltration and enhanced antitumor activities in multiple preclinical models of advanced ovarian cancer, and an early phase I trial (NCT05141253) is ongoing to evaluate PARP inhibitors plus anlotinib as bridging therapy for CAR-T cell therapy in patients with refractory MSLN-positive ovarian cancer.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    USP18 promotes anlotinib resistance in medullary thyroid carcinoma by stabilizing aurora B kinase (Section 27) -  Mar 5, 2024 - Abstract #AACR2024AACR_6804;    
    In summary, overexpressed USP18 can activate PI3K-Akt signaling and promote tumor cell proliferation by increasing the stability of Aurora B kinase, ultimately leading to the formation of Anlotinib resistance in MTC patients. Combined use of Aurora B kinase inhibitor is a potentially effective combined treatment strategy for Anlotinib-resistant MTC patients.
  • ||||||||||  Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal:  Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy. (Pubmed Central) -  Mar 4, 2024   
    We also summarized and reviewed literature reports on PubMed from January 1, 2000, to December 31, 2022, using the keyword "pulmonary blastoma", discussing the efficacy and specifics of chemotherapy and radiotherapy. Immunotherapy, in combination with targeted therapy, should be considered a potential therapeutic strategy for PB.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials. (Pubmed Central) -  Feb 19, 2024   
    Through the generation of cytotoxic cytokines by T lymphocytes, the therapeutic group using anti-PD-1 monoclonal antibodies (anti-PD-1 mAbs) in conjunction with anlotinib and CIK cells was more successful than the group receiving dual therapy. The preclinical study contributes to exploring the therapeutic alternatives for patients with lung adenocarcinoma, thus prolonging their lives.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Combination of radiotherapy and Anlotinib enhances benefit from immunotherapy to liver metastasis and abscopal tumor from lung cancer. (Pubmed Central) -  Feb 8, 2024   
    PPAR signaling pathway were significantly activated and CD8T and dendritic cells (DC) were increased in the triple therapy group compared to the PD-1 inhibitor combined with Anlotinib group. Radiotherapy combined with PD-1 inhibitor and Anlotinib can effectively exert anti-tumor efficacy and reshape the tumor immune microenvironment by increasing the infiltration of anti-tumor immune cells and reducing the infiltration of immunosuppressive immune cells.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Real-world data of anolotinib for lung cancers with liver metastases in China (Congress Hall Foyer) -  Feb 6, 2024 - Abstract #ELCC2024ELCC_510;    
    Conclusions This study provides the largest real-world experience of anlotinib in solid tumors with liver metastases to date. For NSCLC and SCLC with liver metastases, anlotinib could be an effective and safe treatment option.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, Sutent (sunitinib) / Pfizer
    Review, Journal:  Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection. (Pubmed Central) -  Jan 23, 2024   
    Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.
  • ||||||||||  Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
    Enrollment open, Trial initiation date, Monotherapy, Metastases:  A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection  (clinicaltrials.gov) -  Jan 23, 2024   
    P1,  N=75, Recruiting, 
    The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib. Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024